Univar Solutions Selected as Ingredion Pharma Solutions Distributor in United States and Canada [Accessibility Statement] Skip NavigationPharmaceutical manufacturers will benefit from deep expertise and an extensive distribution network paired with Ingredion's functional excipientsDOWNERS GROVE, Ill., Feb. 24, 2026 /PRNewswire/ -- Univar Solutions LLC ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced that its Ingredien ...

湖南景峰医药股份有限公司 关于公司股价可能较大幅度向下除权的第三次风险提示公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000908 证券简称：*ST景峰 公告编号：2026-017 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示： 2026年2月3日，湖南景峰医药股份有限公司（以下简称"公司"或"景峰医药"）收到湖南省常德市中级人 民法院（以下简称"常德中院"）送达的（2025）湘07破15号之一《民事裁定书》，常德中院裁定批准 《湖南景峰医药股份有限公司重整计划》（以下简称《重整计划》）并终止公司重整程序。公司进入重 整计划执行阶段。根据公司初步测算情况，预计重整计划实施后公司股价存在向下除权调整的风险，具 体以公司后续公告为准。敬请投资者理性决策，注意投资风险。 一、公司股价较大幅度向下除权的风险 根据《重整计划》之出资人权益调整方案，公司资本公积金转增股本方案如下：以公司现有总股本 879,774,351股为基数，按照每10股转增10股的比例实施资本公积金转增股本，共计可转增879,774,351股 股票。转增后，公司 ...

证书编号：No. CEP 2024-020 - Rev 00 生产地址：浙江省台州市椒江区外沙路46号 证券代码：600267 证券简称：海正药业 公告编号：临2026-15号 浙江海正药业股份有限公司 关于替格瑞洛原料药获得CEP证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发的替格瑞洛原料药欧洲药典适用性 认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP证书"），现 就相关情况公告如下： 一、CEP证书相关信息 药品名称：TICAGRELOR/替格瑞洛 产品剂型：原料药 发证机构：欧洲药品质量管理局（EDQM） 二、药品的其他相关情况 替格瑞洛适用于急性冠状动脉综合征（ACS）的治 ...

SAN DIEGO--(BUSINESS WIRE)---- $CORT #CORT--The lawsuit alleges that defendants failed to disclose that the FDA raised concerns about the adequacy of evidence supporting relacorilant's NDA. ...

PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN NEURODEGENER ...

For the quarter ended December 2025, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $199.91 million, down 5.9% over the same period last year. EPS came in at $0.47, compared to -$0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $194.37 million, representing a surprise of +2.85%. The company delivered an EPS surprise of +219.14%, with the consensus EPS estimate being -$0.40.While investors scrutinize revenue and earnings changes year-over-year and how th ...

With a market cap of $307.3 billion, Merck & Co., Inc. (MRK) develops and markets a broad portfolio of human health pharmaceuticals and vaccines across areas such as oncology, infectious diseases, cardiometabolic disorders, and immunology, alongside a robust animal health business serving livestock and companion animals. Companies valued at more than $200 billion are generally classified as “mega-cap” stocks, and Merck & Co. fits this criterion perfectly. The company also advances innovation through stra ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. LongBio Pharma (Suzhou) Co., Ltd. 天辰生物醫藥（蘇州）股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) W ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shandong Hanfang Pharmaceutical Co., Ltd. 山東漢方製藥股份有限公司 (A joint stock company incorporated in the People's Republic ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Zhejiang Jingxin Pharmaceutical Co., Ltd. 浙 江 京 新 藥 業 股 份 有 限 公 司 (A joint stock company incorporated in the People's Republic of China with limit ...